| Milestones / Highlights |
| 2023 |
- Submission of DBPR108(prusogliptin) as a New Drug Application (NDA) for registration
|
| 2022 |
- Initiation of Phase Ib clinical trial of DBPR112(ABT-101)
- Identification of DBPR376 as an anti-cancer drug delivery system drug candidate
- Identification of DBPR22998 a isoQC inhibitor as an anti-cancer drug candidate
- Identification of DBPR901 a humanized anti-eHSP90α mAb as an anti-cancer drug candidate
|
| 2021 |
- Completion of phase III clinical trial of DBPR108
- IND approvals of DBPR115(T-1201) by US FDA and TFDA and initiation of Phase I clinical trial in Taiwan
- IND approval by US FDA and TFDA, and initiation of Phase I clinical trial of DBPR216(T-1301)
- Technology transfer of DBPR211(AGTX-2004) to Applied Biopharma LLC, the subsidiary of Agentix Corp in the US
- Technology transfer of DBPR215 to Jiayi Biomedical Co., Ltd.
- Technology transfer of DBPR114(LXP1788) to LaunXP Biomedical Co., Ltd.
- Identification of DBPR168 an agent against chemotherapy-induced peripheral neuropathy as a neuroprotective drug candidate
- Identification of DBPR728 an aurora kinase inhibitor which reduces levels of MYC oncoproteins as an anti-cancer drug candidate
- Technology transfer of DBPR186(T-1501) to Taivex Therapeutics Co.
|
| 2020 |
- Technology transfer of DBPR112(ABT-101) to Anbogen Therapeutics
- Identification of DBPR186 an PS-targeting drug conjugate as an anti-cancer drug candidate
- Joined Anti-COVID-19 Drug Development Program with ATRI
|
| 2019 |
- Initiation of Phase III clinical trials of DBPR108
- Technology transfer of DBPR216(T-1301) to Taivex Therapeutics Co.
- Identification of DBPR807 an CXCR4 antagonist as a HCC/AMI/PBSCT drug candidate
- Relocation of VMIC lab to the National Biotechnology Research Park (NBRP), Nangang
|
| 2018 |
- Completion of Phase I clinical trial of DBPR112 in Taiwan
|
| 2017 |
- Initiation of Phase II clinical trial of DBPR108
- Initiation of repeat-dose Phase I clinical trial of DBPR112 in Taiwan
- IND approvals of DBPR114 by US FDA and TFDA
- IND approval of DBPR211 by TFDA
- Identification of DBPR117 the 1st biologics anti-RSPO3 mAb as an anti-cancer drug candidate
- Establishment of VMIC contingent lab at NHRI Zhunan campus
|
| 2016 |
- Identification of DBPR116 an opioid receptor modulator as a pain control drug candidate
- Identification of DBPR216 a c-KIT inhibitor as an anti-cancer drug candidate
- IND approvals of DBPR112 by US FDA and TFDA
- IND approval of DBPR211 by US FDA
- Technology transfer of DBPR115(T-1201) to Taivex Therapeutics Co.
- Establishment of The Platforms of Technology Service
|
| 2015 |
- IND approval of DBPR108 by CFDA and initiation of Phase I clinical trial
- IND approvals of Phase II clinical trials of DBPR104(SB01) by US FDA and TFDA and initiation of Phase II clinical trial in Taiwan
- IND approval of DBPR110 by US FDA
- Identification of DBPR115 a PS-targeting drug conjugate as an anti-cancer drug candidate
- Identification of DBPR215 a CXCR4 antagonist as a PBSCT drug candidate
|
| 2014 |
- Identification of DBPR114 a multi-kinases inhibitor as an anti-cancer drug candidate
- IND approval of DBPR108 by TFDA and initiation of a Phase I clinical trial of repeated doses of DBPR108 in Taiwan
|
| 2013 |
- Technology transfer of DBPR110 to MICROBIO Co.
|
| 2012 |
- IND approvals of DBPR108 by US FDA and TFDA and initiation of a Phase I clinical trial of single dose DBPR108 in Taiwan
- Identification of DBPR112 an EGFR inhibitor as an anti-cancer drug candidate
- Technology transfer of DBPR108 to Genovate Biotechnology Co. and the P-Team
- Starting to join the Technology Development Program (TDP) for Nonprofit Research Organization funded by Ministry of Economic Affairs (MOEA)
|
| 2011 |
- Identification of DBPR211 a peripheral CB1 receptor antagonist as an anti-diabetes drug candidate
- Initiation of Phase I clinical trial of DBPR104(SB01) in Taiwan
|
| 2010 |
- IND approvals of DBPR104(SB01) by US FDA and TFDA
- Reorganized in to Institute of Biotechnology and Pharmaceutical Research in August
- Identification of DBPR110 a NS5A inhibitor as an anti-HCV drug candidate
|
| 2009 |
- Approval of DBPR108 by the Center for Drug Evaluation as Critical Path Program Index Case of 2009
- Establishment of Pharmaceutical Development Lab in IBPR
- Initiation of program “Pre-clinical and Clinical Development of Novel Anti-diabetic Drug Candidate, DBPR108”
|
| 2008 |
- 2008 International Symposium on Influenza Virus
- Approvals of DBPR104(SB01) & DBPR204(SB02) by the Center for Drug Evaluation as Critical Path Program Index Cases of 2008
- Identification of DBPR108 a inhibitor as an anti-diabetes drug candidate
- “Pre-clinical and Clinical Development of Novel Anti-Diabetic Drug Candidate, DBPR108” program granted as the Case of Promoting Successful Biotech Investment by the Executive Yuan, Republic of China (Taiwan)
- Technology Transfer of DBPR104(SB01) & DBPR204(SB02) to SynCore Biotechnology Co., Ltd (a new company and subsidiary of the Sinphar Group)
- Collaboration with Genovate Biotechnology Co. and Genelabs Technologies Inc. on HCV drug discovery
|
| 2007 |
- 2007 International Symposium on the Influenza Virus
- Initiation of new target-based cancer drug discovery projects
- Approvals of DBPR104 & DBPR204 by the Center for Drug Evaluation as Critical Path Program Index Cases of 2007
|
| 2006 |
- Initiation of Discovery and development of Anti-obesity Drugs of Central CB1 Antagonists (an industry-research collaborative project)
- Initiation of Anti-influenza Drug Discovery Program (teamed up with Chang Gung University, National Tsing Hua University and Academia Sinica)
|
| 2005 |
- 1st technology transfer project (DBPR303, sodium stibogluconate)
- Completed of “Synthetic Rehearsal of Manufacturing Process of Tamiflu”
|
| 2004 |
- 1st ROC patent granted (anti-enterovirus compound; TWI203254)
- Identification of DBPR104 & DBPR204 vascular disrupting agents as anti-cancer drug candidates
- Labs relocation to NHRI Zhunan campus
|
| 2003 |
- Joined Anti-SARS Drug Development Program
- Identification of DBPR103 & DBPR203 as anti-EV71 drug candidates
- Identification of DBPR303 as anti-HCV drug candidate
- 1st US patent granted (anti-enterovirus compound;US6,706,739B2)
|
| 2002 |
- Labs relocation to National Defense Medical Center
- 1st US patent application (anti-enterovirus compound)
- 1st ROC patent application (anti-enterovirus compound)
|
| 1999 |
- Establishment of animal pharmacology and pharmacokinetics labs
|
| 1998 |
- Division of Biotechnology and Pharmaceutical Research was founded in January 1998
- Establishment of high throughput screening Lab
- Establishment of chemistry lab
|
